COMPARISON OF ROSUVASTATIN AND ATORVASTATIN IN ACHIEVING THE TREATMENT GOALS OF DYSLIPIDEMIA
Naresh Jyoti, Poonam, Jaswant Rai, Sharanjit Kaur, Ashok Dhillon

1. Assistant Professor, Department of Pharmacology, Chintpurni Medical College & Hospital, Pathankot (Pb.)
2. Associate Professor, Department of Anatomy, Chintpurni Medical College & Hospital, Pathankot (Pb.)
3. Prof & Head, Department of Pharmacology, Government Medical College, Amritsar (Pb.).
4. Assistant Professor, Department of Pharmacology, Chintpurni Medical College & Hospital, Pathankot (Pb.)
5. Senior Resident, Department of Medicine, Chintpurni Medical College & Hospital, Pathankot (Pb.)

CORRESPONDING AUTHOR
Dr. Naresh Jyoti,
Asst. Professor, Department of Pharmacology,
Chintpurni Medical College & Hospital,
Pathankot (Pb.).
E-mail: nareshdel@yahoo.com
Ph: 0091 9779115349

ABSTRACT: CONTEXT (BACKGROUND): Dyslipidemia has been recognized as main reason for development of atherosclerosis and coronary artery disease. Statin group of drugs are most commonly prescribed for the treatment of dyslipidemia. Among them atorvastatin and relatively new drug rosuvastatin are prescribed more frequently. AIM: The aim of the study was to compare effectiveness of rosuvastatin and atorvastatin in dyslipidemia and achieving the treatment goals set by ATP III and Asian Indian Guidelines.

SETTING AND DESIGN: This 12 weeks, open label, randomized study was conducted at the Department of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India.

METHODS AND MATERIAL: Patients aged 30 – 70 years with dyslipidemia were eligible. Patients were assigned one of two treatment groups. Group I received atorvastatin and group II received atorvastatin. Both drugs were given in dose 10 mg/d for 12 weeks. The lipid profile low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-high density lipoprotein cholesterol (non HDL-C), triglycerides (TG) and very low density lipoprotein cholesterol (VLDL-C) were measured before the start of therapy and after 12 weeks. Percentage changes from baseline were calculated and adverse effects were recorded.

STATISTICAL ANALYSIS USED: Paired Student’s 't' test was applied within the group after treatment interval and unpaired 't' test is applied when 2 groups are compared.

RESULTS AND CONCLUSIONS: Sixty patients (31 men, 29 women) were enrolled; 30 patients per treatment group. In group I, mean percentage decrease in levels of TC, LDL-C, non-HDL-C, TG and VLDL-C were 28.15%, 30.77%, 37.28%, 50.75% and 50.75% respectively whereas mean percentage increase in HDL-C was 32.15% at 12 weeks. In group II, mean percentage decrease in levels of TC, LDL-C, non-HDL-C, TG and VLDL-C were 42.26%, 49.03%, 51.15%, 60.91% and 60.91% respectively whereas mean percentage increase in HDL-C was 29.26%. Myalgia, nausea, vomiting and headache were the adverse effects observed in both groups. Rosuvastatin is more effective than atorvastatin in achieving the targets of TC (100% vs 96.66%), LDL-C (100% vs 53.33%) set by ATP III guidelines and targets of TC (73.33% vs 6.66%), LDL-C (66.66% vs 3.33%) respectively set by Asian Indian guidelines.

KEY WORDS: atorvastatin, rosuvastatin, dyslipidemia, treatment goals
INTRODUCTION: Dyslipidemia has been recognized as the foundation for atherosclerosis and development of coronary artery disease. The risk of CAD in Indians is 3-4 time higher than White Americans, 6 times higher than Chinese and 20 times higher than Japanese.

The United States National Cholesterol Education Programme-Adult Treatment Panel has issued guidelines from time to time to manage dyslipidemia so as to decrease the incidence of CAD. These guidelines based on the prevalent dyslipidemic picture in the population help to define the treatment goals in patients by setting the desired values for the various lipid profile parameters. The latest report of adult treatment panel (ATP III) focuses on primary prevention of dyslipidemia in persons with multiple risk factors.

These guidelines are more applicable to the western population and are not suited for the Indian population as the latter has a different lipid profile and risk factors. Incidence of CAD among Asian Indian is 3-4 times higher than the white population. In the Indian population, more strict control of lipid profile is needed. The new goals are proposed for Asian Indians which are more strict. These goals are modified from NCEP 164 report and values are about 20% less than ATP III guidelines.

The initial approach to a patient of dyslipidemia is modifications in lifestyle i.e. diet modification (low fat consumption), weight loss, physical activity, smoking cessation, aggressive control of diabetes and hypertension. If these changes do not suffice then pharmacotherapy has to be implemented. The drugs available for use are HMG-CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, fibrin acid derivatives and probucol. In addition to these there are indigenous drugs like husk of Plantago ovata (Ispaghula husk), Trigonella foenumgraecum seeds (Fenugreek) etc.

Out of these drugs, simvastatin and atorvastatin are commonly prescribed drugs for dyslipidemia. Rosuvastatin is a relatively newer member of statins which is more expensive than existing members of statins and its prescription is also on the rise. That is why in the present study rosuvastatin has been included. Atorvastatin has been taken as a standard drug due to the fact that it is more frequently and has been reported to be better drug in dyslipidemia over other members of statin group. All of these factors have formed the basis of present study in which effect of rosuvastatin and atorvastatin on lipid profile has been compared in addition to their safety in dyslipidemic patients.

AIMS AND OBJECTIVES: The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid profile in non-diabetic dyslipidemia in achieving the goals as per ATP III and Indian Guidelines.

MATERIAL AND METHODS: The plan of the study was submitted to the Institutional Ethics Committee and approval was sought. After the approval of the Ethics Committee, patients were recruited from Medicine Department of Guru Nanak Dev Hospital, Amritsar in the age group of 30-70 years. A total 60 patients were enrolled for the study.

SELECTION CRITERIA: A total of 60 patients within the age group of 30-70 years with abnormal lipid profile (serum total cholesterol >200 mg%, LDL-C >100 mg% or HDL-C <35 mg%) attending Medical OPD/Ward of Guru Nanak Dev Hospital attached to Government Medical College, Amritsar were enrolled in study. The consent of the patients was obtained after fully explaining the details of study procedures to them.
DRUGS TO BE INVESTIGATED

1. Tab Rosuvastatin 10 mg once daily.
2. Tab Atorvastatin 10 mg once daily.

Each of these was given for 12 weeks

EXCLUSION CRITERIA:

Patients are excluded from the study if they are:

1. Hypersensitive to rosuvastatin or atorvastatin.
3. Pregnant and lactating women.
4. Women on oral contraceptive pills (OCPs) estrogen/hormone replacement therapy.
5. Having history of muscle pain (fibromyalgia with associated raised CPK levels.
6. Patients with abnormal liver function test (LFT) and renal function test (RFT).
7. Concurrently using of Cyp 3 A4 isoenzyme i.e. azole antifungals, macrolides, calcium channel blockers (except dihydropyridines e.g. nifedipine, amlodipine), cyclosporine, histamine-2 blockers, grape fruit juice and enzyme inducers like phenobarbitone, rifampicin, phenytoin, carbamazepine.

DESIGN OF THE STUDY: The study was a randomized, open label, and parallel study. In this study after getting initial baseline, overnight fasting lipid levels at the start (week 0) of the study, and subsequent levels were obtained at 12th week of the study.

After enrollment history of patients was taken and physical examination was done. Total 60 patients were divided randomly into two groups of 30 patients each and assigned as group I and Group II. Group I received atorvastatin (10 mg tablet OD) and Group II received rosvustatin (10 mg tablet OD) for 12 weeks. In both the groups, patients were instructed to take drug 30 minutes before evening meal.

The patients were advised to continue with their dietary modification and physical activity and they were explained the schedule of the drug treatment. The patients were also advised to report immediately in case they developed unexplained muscle pain/undue tiredness, low urine output or any other symptoms pertaining to side effects of the drugs. At the end of the study, the patients were kept under regular follow up to monitor adverse events for additional 6 weeks with the Department of Pharmacology and Medicine, Government Medical College, Amritsar.

PARAMETERS AND LABORATORY PROCEDURES: The study was conducted by initially recording the baseline investigations in each patient and subsequently doing investigations at 12th weeks. The patients were also instructed to visit the hospital at 6 weeks to monitor any adverse reaction or to report any time in case of adverse event. The history of the patient, clinical examination and adverse events were recorded on each patient visit and blood samples were drawn for estimation of lipid profile at 0 week and 12th week after overnight fasting for 12 hours.

The investigations were carried out in the Department of Pharmacology using proprietary kit methods. The instrument used for analysis of blood samples was spectrophotometer. After taking samples the serum was assayed with the help of a centrifuge machine by rotating it at 2000 revolutions per minute, for 10 minutes at 37°C and serum was used to determine TC levels followed by HDL-C levels after precipitation of VLDL-C and LDL-C.
Blood samples were analysed using a spectrophotometer by CHOD/POD-phosphotungstate method. Very low density lipoprotein Cholesterol (VLDL-C) was calculated by formula

\[ \text{VLDL-C} = \frac{\text{Triglycerides}}{5} \]

Low density lipoprotein cholesterol (LDL-C) was calculated by using Friedewald’s formula

\[ \text{LDL-C (mg/dl)} = \text{T.C (mg/dl)} - \text{HDL-C (mg/dl)} - \frac{\text{Triglycerides}}{5} \]

Non-HDL-C was calculated by: TC – HDL-C

**STATISTICAL ANALYSIS:** Data generated from the study was evaluated and expressed as mean± SD of each variable. Paired Student’s ‘t’ test was applied within the group after treatment interval and unpaired ‘t’ test was applied when 2 groups were compared.

**OBSERVATIONS AND RESULTS:** The observations were tabulated as mean± standard deviation and analysis was done using student’s ‘t’ test and level of significance was determined by its ‘p’ value. ‘p’ value <0.05 was taken as statistically significant.

**DISCUSSION:** Clinically dyslipidemia is presented by levels of TC > 200mg/dl, LDL-C > 100mg/dl, TG >150mg/dl and HDL-C <40mg/dl in a patient with CAD. In non-CAD patients, the levels of these parameters are determined by presence of one or more risk factors. Dyslipidemia is one of the major risk factor for the causation of CAD and the aim of drug therapy for dyslipidemia is to bring the levels of these parameters in desirable range. Presently statins are the commonly prescribed drugs for the treatment of this disorder.

In various comparative clinical studies, atorvastatin has been proved to be better than simvastatin which has been claimed to be a better agent than the existing members of the family.

In the present study, atorvastatin and rosuvastatin, both HMG-CoA reductase inhibitors have been studied as monotherapy in the patients of dyslipidemia.

Both these drugs have been shown to exert its major effect on lowering of serum TC and LDL-C levels.

Group I and Group II with 30 patients each participated in the study with average age for group I being 54.9 ± 11.42 years and for group II 52.33 ± 8.43 years.

The mean serum total cholesterol levels at the beginning of the study were 241.62 ± 29.57 mg/dl. These levels were significantly higher than the mean TC levels of 157 ± 29 mg/dl as reported by Gandhi, in a study of 201 healthy urban Delhi subjects. These levels were also higher than the levels as reported by Gopinath et al in patients of CAD who had reported values of 210 mg/dl and 169 mg/dl in urban and rural area respectively.

The mean levels of serum HDL-C reported at the beginning of the study were 31.63 ± 5.9 mg/dl. These levels were lower than the levels reported by Gopinath et al who reported serum HDL-C of 56 ± 13 mg/dl in urban and 51 ± 9 mg/dl in rural subjects and levels reported by Gupta et al who reported higher levels in rural men as compared to urban men (44.0 ± 13 vs 43.1 ± 12 mg/dl).

The mean serum LDL-C levels and TG levels at initiation of the study were 145.19 ± 24.89 and 325.91 ± 88.55 mg/dl respectively. Mean VLDL-C levels reported at the beginning of the study 65.18 ± 17.7 mg/dl.
GROUP I: In the present study atorvastatin 10 mg/day for 12 weeks resulted in statistically significant fall in levels of serum TC and LDL-C by 28.15% and 30.77% (Table IV). This fall was lower than 33% and 42% as reported by Noseda et al\textsuperscript{19} with 10mg/day of atorvastatin at 12 weeks. This fall is almost similar to the fall reported by Mckenney et al\textsuperscript{20} who reported fall of 26% and 30% for serum TC and LDL-C with use of atorvastatin 10 mg/day for 12 weeks.

Atorvastatin decreased the serum TG by 50.75% in 12 weeks which significantly more than 25% decrease in serum TG after 12 weeks use of atorvastatin as reported by Tiek C. Ooi et al.\textsuperscript{21} On analysing the effect of atorvastatin on serum VLDL-C, it was found that serum VLDL-C decreased by 50.75% at 12 weeks. This fall at 12 weeks was higher than the fall as reported by Tiek C. Ooi et al\textsuperscript{21} who reported a fall of 35% in VLDL-C levels after 12 weeks administration of atorvastatin 10 mg/day.

The rise in levels of serum HDL-C by atorvastatin at the end of 12 weeks was 32.15%. This rise is significantly more than 10% as reported by Frost et al.\textsuperscript{22}

GROUP II: The levels of serum TC and LDL-C are decreased by 42.26% and 49.03% respectively with the use of rosuvastatin after 12 weeks (Table IV). This fall in TC is more than the fall reported by Blasetto et al\textsuperscript{23} who reported a fall in TC by 34%. But fall in LDL-C is almost similar to 48.1% as reported by Blasetto et al\textsuperscript{23} and 48% as reported by Ballantyne et al.\textsuperscript{24} On analyzing the effect of rosuvastatin on levels of TG and HDL-C an extremely significant fall of 60.91% and 35.69% respectively was reported after 12 weeks. This fall was significantly higher than 28.8% and 12.9% respectively as reported by Blasetto et al\textsuperscript{23} who also stated that patients with elevated TG appeared to have greater percentage decrease in TG levels and greater percentage increase in HDL-C than do those with lower TG. This fall in TG and HDL-C was also significantly higher than 23% and 10% respectively as reported by Ballantyne et al.\textsuperscript{24}

SAFETY PROFILES: Both drugs were well tolerated. Nausea/vomiting, headache and myalgia (mild muscle pain) were reported in few patients in both groups but difference was not significant. Apart from these, no other side effect was noticed in 12 weeks of the study.

GOALS ACHIEVED AFTER 12 WEEKS: The goals achieved after 12 weeks of treatment, were compared with ATP III and Asian Indian Guidelines.

It was seen that in Group I, 96.66% of patients achieved TC target while 53.33% of patients achieved LDL-C target set by ATP III guidelines. In group II, 100% patients achieved both TC and LDL-C targets set by ATP III (Table V).

On the other hand when values at 12 weeks were compared with Asian Indian Guidelines it was found that in group I, 6.66% of patients achieved TC target and 3.33% achieved LDL-C target considered to be desirable by Asian Indian Guidelines (Table VI).

In group II, 73.33% of patients achieved TC target and 66.66% of patients achieved LDL-C goal set by Asian Indian Guidelines.

So it is clear that in group II more patients achieved ATP III and Asian Indian Goals as compared to Group I after 12 weeks of treatment.

REASON FOR BETTER EFFICACY OF ROSUVASTATIN: Rosuvastatin is a significantly more potent blocker of hepatocyte sterol than all other statins currently available. It differs structurally from other statins, containing a polar methane sulphonamide group which confers...
relative hydrophilicity, which in turn imparts greater selectivity for uptake into hepatic versus non-hepatic cells.\textsuperscript{25}

**CONCLUSION:** Rosuvastatin had an overall better effect on lipid profile than atorvastatin. It lowers serum TC, LDL-C, TG and VLDL-C to significantly greater extent than atorvastatin but its efficacy is equal to atorvastatin when change in HDL-C levels is considered. Rosuvastatin is more effective than atorvastatin in achieving the targets of TC (100\% vs 96.66\%), LDL-C (100\% vs 53.33\%) set by ATP III guidelines and targets of TC (73.33\% vs 6.66\%), LDL-C (66.66\% vs 3.33\%) respectively set by Asian Indian guidelines. It can be concluded that rosuvastatin is more effective in achieving guidelines goals as compared to atorvastatin.

From these observations it can also be concluded that atorvastatin can be recommended in mild or borderline cases whereas rosuvastatin in patients with high and very high lipid levels.

Multiple studies across the country taking into consideration the ethnic, dietary, genetic and cultural variability are needed in establishing the validity and relevance of these observations and recommendations.

**REFERENCES:**


23. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of Rosuvastatin compared with other Statins at Selected starting doses in Hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003;91:3C-10C.


### TABLE I
Modified goals proposed for Asian-Indians

<table>
<thead>
<tr>
<th>Category</th>
<th>LDL-C</th>
<th>TC</th>
<th>Non-HDL-C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimum</td>
<td>&lt;80</td>
<td>&lt;150</td>
<td>&lt;110</td>
</tr>
<tr>
<td>Near or above optimal</td>
<td>80-99</td>
<td>150-169</td>
<td>110-129</td>
</tr>
<tr>
<td>Borderline high</td>
<td>100-114</td>
<td>170-184</td>
<td>130-144</td>
</tr>
<tr>
<td>High</td>
<td>115-129</td>
<td>185-199</td>
<td>145-159</td>
</tr>
<tr>
<td>Very high</td>
<td>&gt;130</td>
<td>&gt;200</td>
<td>&gt;160</td>
</tr>
</tbody>
</table>

### TABLE II

<table>
<thead>
<tr>
<th></th>
<th>MEAN AGE (YEARS ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>54.9 ± 11.42</td>
</tr>
<tr>
<td>Group II</td>
<td>52.33 ± 8.43</td>
</tr>
</tbody>
</table>

The mean age was slightly less in the group II as compared to group I

### TABLE III

<table>
<thead>
<tr>
<th>Sex</th>
<th>Group I (%)</th>
<th>Group II (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>19 (63%)</td>
<td>12 (40%)</td>
</tr>
<tr>
<td>Female</td>
<td>11 (37%)</td>
<td>18 (60%)</td>
</tr>
</tbody>
</table>

### TABLE IV: Lipid levels (mg/dl) and comparative percentage changes in Indian patients before and after 12 weeks of therapy.

<table>
<thead>
<tr>
<th>Parameter (mg/dl)</th>
<th>Percentage Change</th>
<th>Group I (n=30) {Mean ± SD}</th>
<th>Group II (n=30) {Mean ± SD}</th>
<th>Comparative Difference of Change between Group I and II</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>Week 0</td>
<td>241.1 ± 26.51</td>
<td>242.14 ± 32.63</td>
<td>14.11*</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>173.23 ± 17.81</td>
<td>139.8 ± 14.17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>% change</td>
<td>28.15</td>
<td>42.26</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t value</td>
<td>31.48</td>
<td>23.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>p value</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>LDL-C</td>
<td>Week 0</td>
<td>143.16 ± 20.37</td>
<td>147.23 ± 29.42</td>
<td>18.26*</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>99.1 ± 8.53</td>
<td>75.03 ± 9.49</td>
<td></td>
</tr>
<tr>
<td></td>
<td>% change</td>
<td>30.77</td>
<td>49.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t value</td>
<td>18.29</td>
<td>16.71</td>
<td></td>
</tr>
<tr>
<td></td>
<td>p value</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>HDL-C</td>
<td>Week 0</td>
<td>32.16 ± 6.12</td>
<td>31.1 ± 5.71</td>
<td>2.89*</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>42.5 ± 5.01</td>
<td>40.2 ± 7.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>% change</td>
<td>32.15</td>
<td>29.26</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t value</td>
<td>11.49</td>
<td>9.95</td>
<td></td>
</tr>
<tr>
<td></td>
<td>p value</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE V

**GOALS ACHIEVED AT 12 WEEKS (NCEP ATP III GUIDELINES)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group I</th>
<th>Group II</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>29 (96.6%)</td>
<td>30 (100%)</td>
</tr>
<tr>
<td>LDL-C</td>
<td>16 (53.33%)</td>
<td>30 (100%)</td>
</tr>
</tbody>
</table>

### TABLE VI

**GOALS ACHIEVED AT 12 WEEKS (ASIAN INDIAN GUIDELINES)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group I</th>
<th>Group II</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>2 (6.66%)</td>
<td>22 (73.33%)</td>
</tr>
<tr>
<td>LDL-C</td>
<td>1 (3.33%)</td>
<td>20 (66.66%)</td>
</tr>
</tbody>
</table>

*Difference in percentage change between group I and group II*